This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting: A Great Opportunity for Early Career Psychiatrists

John M. Kane, MD; Lauren D. Hill, PhD; Bruce J. Kinon, MD; William Z. Potter, MD, PhD; Mark H. Rapaport, MD; and Nina R. Schooler, PhD

Published: April 15, 2012

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

When the Early Clinical Drug Evaluation Unit meeting was first held over a half century ago, psychopharmacology and indeed modern-day psychiatry were in their infancy, yet there was enormous excitement surrounding the introduction of new medications that appeared to have a profound impact on major psychiatric illnesses. Perhaps the most publicized effect was the control of the florid symptoms of psychosis that was used as a basis for moving the majority of patients with schizophrenia to outpatient settings as an alternative to long-term hospitalizations. Even then, it was realized that much more needed to be done and that it was in the public interest for government to invest in methods for developing effective treatments for serious mental illnesses.

J clin Psychiatry2012; 73(4):504-505

© 2012 Physicians Postgraduate Press, Inc.’ ‹

Volume: 73

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF